



Commercial/Healthcare Exchange PA Criteria

Effective: March 30, 2023

Prior Authorization: Jaypirca (pirtobrutinib)

Products Affected: Jaypirca (pirtobrutinib) oral tablets

Medication Description: JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

Covered Uses: treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

Exclusion Criteria: None

Required Medical Information:

1. Diagnosis
2. Past therapies tried/failed

Prescriber Restriction: Medication must be prescribed by, or in consultation with, an oncologist

Age Restriction: 18 years and older

Coverage Duration: 12 months

Other Criteria:

Initial Approval Criteria

Initial Criteria

1. **Mantle Cell Lymphoma.** Approve for 1 year if the patient meets the following criteria (A, B, **and** C):

- A. Patient is \geq 18 years of age; **AND**
- B. Patient has tried at least one systemic regimen; **AND**

Note: Examples of a systemic regimen contain one or more of the following products: rituximab, dexamethasone, cytarabine, carboplatin, cisplatin, oxaliplatin, cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, bendamustine, Velcade (bortezomib intravenous or subcutaneous injection), lenalidomide, gemcitabine, and Venclaxta (venetoclax tablets).

- C. Patient has tried one Bruton tyrosine kinase inhibitor (BTK) for mantle cell lymphoma.

Note: Examples of BTK inhibitors indicated for mantle cell lymphoma include Brukinsa (zanubrutinib capsules), Calquence (acalabrutinib capsules), and Imbruvica (ibrutinib capsules, tablets, and oral suspension).

March 2023



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 2



References:

1. Product Information: JAYPIRCA™ oral tablets, pirtobrutinib oral tablets. Lilly USA LLC (per FDA), Indianapolis, IN, 2023.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	03/30/2023